Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On December 1, 2022, China Pharma Holdings, Inc. (the "Company") received a
notification (the "Deficiency Letter") from the NYSE American LLC (the "NYSE
American") stating that the Company was not in compliance with a certain NYSE
American continued listing standard relating to stockholders' equity, or
Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer
to have stockholders' equity of $4.0 million or more if it has reported losses
from continuing operations and/or net losses in its four most recent fiscal
years. The Deficiency Letter noted that Company had stockholders' equity of $2.8
million as of September 30, 2022, and has reported losses from continuing
operations and/or net losses in its four most recent fiscal years ended December
31, 2021.
The Company remains subject to several deficiencies and/or incompliance as
disclosed in the current report on Form 8-K dated June 22, 2022 (Initial Equity
Notification) and the current report on Form 8-K dated September 30, 2022 (Price
Noncompliance Notification) for the price noncompliance. In addition, the
Company remains subject to the Plan Acceptance dated August 29, 2022 in which
NYSE American accepted the Company's plan (the "Plan") for curing the
stockholders' equity noncompliance under Section 1003(a)(iii). Therefore, if the
Company is not in compliance with all stockholders' equity standards by December
15, 2023 or does not make progress consistent with the Equity Plan during the
Plan period, the exchange will initiate delisting proceedings as appropriate.
Furthermore, if the Company is not in compliance with the price standard by
March 26, 2023, the exchange will initiate delisting proceedings as appropriate.
The Company's common stock, par value $0.001 per share ("Common Stock") will
continue to be listed on the NYSE American while it attempts to regain
compliance with the listing standards noted, subject to the Company's compliance
with other continued listing requirements. The Common Stock will continue to
trade under the symbol "CPHI". However, the Company will continue to be included
in the list of NYSE American noncompliant issuers and the .BC indicator will
continue to be disseminated with the Company's ticker symbol(s). The website
posting and .BC indicator will be removed when the Company has regained
compliance with all applicable continued listing standards. The NYSE American
notification does not affect the Company's business operations or its SEC
reporting requirements and does not conflict with or cause an event of default
under any of the Company's material agreements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following are filed as exhibits to this report:
Exhibit No. Description
99.1 Press Release dated December 2, 2022, announcing the receipt of
notice of noncompliance from NYSE American.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
1
© Edgar Online, source Glimpses